## Meral Esen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10785187/publications.pdf

Version: 2024-02-01

		201674	175258
52	2,947 citations	27	52
papers	citations	h-index	g-index
			4007
53	53	53	4297
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens. Npj Vaccines, 2022, 7, .	6.0	3
2	Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial. Malaria Journal, 2022, 21, .	2.3	3
3	Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon. Wiener Klinische Wochenschrift, 2021, 133, 500-508.	1.9	14
4	Epidemiology of dengue fever in Gabon: Results from a health facility-based fever surveillance in Lambaréné and its surroundings. PLoS Neglected Tropical Diseases, 2021, 15, e0008861.	3.0	6
5	Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nature Communications, 2021, 12, 2518.	12.8	34
6	Association of low birth weight and polyparasitic infection during pregnancy in Lambaréné, Gabon. Tropical Medicine and International Health, 2021, 26, 973-981.	2.3	6
7	Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2. PLoS Neglected Tropical Diseases, 2021, 15, e0009361.	3.0	13
8	Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients. Scientific Reports, 2021, 11, 14471.	3.3	15
9	Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. Tropical Medicine and International Health, 2020, 25, 380-386.	2.3	15
10	Impact of Helminth Infections during Pregnancy on Vaccine Immunogenicity in Gabonese Infants. Vaccines, 2020, 8, 381.	4.4	8
11	Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. Vaccine, 2020, 38, 4263-4272.	3.8	9
12	Diagnostic Techniques of Soil-Transmitted Helminths: Impact on Control Measures. Tropical Medicine and Infectious Disease, 2020, 5, 93.	2.3	40
13	Causes of fever in Gabonese children: a cross-sectional hospital-based study. Scientific Reports, 2020, 10, 2080.	3.3	7
14	First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. Clinical Infectious Diseases, 2019, 69, 1509-1516.	5.8	111
15	Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007324.	3.0	7
16	Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. Clinical Infectious Diseases, 2019, 69, 1377-1384.	5.8	53
17	Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. Journal of Infectious Diseases, 2018, 217, 1750-1760.	4.0	132
18	Evaluating dengue burden in Africa in passive fever surveillance and seroprevalence studies: protocol of field studies of the Dengue Vaccine Initiative. BMJ Open, 2018, 8, e017673.	1.9	29

#	Article	IF	CITATIONS
19	Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. American Journal of Tropical Medicine and Hygiene, 2018, 98, 508-515.	1.4	60
20	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature, 2017, 542, 445-449.	27.8	332
21	Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & Dell activity in Beninese primigravidae. Vaccine, 2017, 35, 3474-3481.	3.8	16
22	Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon. Malaria Journal, 2017, 16, 176.	2.3	11
23	Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections. PLoS Pathogens, 2016, 12, e1005538.	4.7	54
24	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clinical Immunology, 2016, 169, 16-27.	3.2	90
25	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and $\langle i \rangle$ post-hoc $\langle i \rangle$ correlate of protection analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 3043-3055.	3.3	5
26	A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. Vaccine, 2016, 34, 4536-4542.	3.8	86
27	A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children. Vaccine, 2016, 34, 5384-5390.	3.8	9
28	Sporozoite Route of Infection Influences In Vitro <i>var</i> Gene Transcription of <i>Plasmodium falciparum</i> Parasites From Controlled Human Infections. Journal of Infectious Diseases, 2016, 214, 884-894.	4.0	17
29	Dengue and chikungunya seroprevalence in Gabonese infants prior to major outbreaks in 2007 and 2010: A sero-epidemiological study. Travel Medicine and Infectious Disease, 2016, 14, 26-31.	3.0	17
30	Natural infection of Plasmodium brasilianum in humans: Man and monkey share quartan malaria parasites in the Venezuelan Amazon. EBioMedicine, 2015, 2, 1186-1192.	6.1	115
31	Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. Open Forum Infectious Diseases, 2015, 2, ofv067.	0.9	39
32	Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malaria Journal, 2015, 14, 117.	2.3	114
33	Influenza A and Parvovirus B19 Seropositivity Rates in Gabonese Infants. American Journal of Tropical Medicine and Hygiene, 2015, 93, 407-409.	1.4	2
34	Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial. PLoS Neglected Tropical Diseases, 2015, 9, e0003768.	3.0	21
35	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. Journal of Infectious Diseases, 2014, 209, 1873-1881.	4.0	206
36	Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial. Vaccine Journal, 2014, 21, 271-279.	3.1	9

#	Article	IF	CITATIONS
37	Influenza symptoms and their impact on elderly adults: randomised trial of <scp>AS</scp> 03â€adjuvanted or nonâ€adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza and Other Respiratory Viruses, 2014, 8, 452-462.		24
38	A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato. Vaccine Journal, 2014, 21, 1490-1499.	3.1	36
39	ASO3-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infectious Diseases, The, 2013, 13, 485-496.	9.1	143
40	Atypical and classical memory B cells produce <i>Plasmodium falciparum</i> neutralizing antibodies. Journal of Experimental Medicine, 2013, 210, 389-399.	8.5	200
41	The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas. Journal of Infectious Diseases, 2013, 208, 479-488.	4.0	60
42	Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infectious Diseases, The, 2013, 13, 680-689.	9.1	84
43	Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine, 2012, 30, 7621-7624.	3.8	48
44	A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals. Malaria Journal, 2012, 11, 367.	2.3	5
45	Effect of IL-15 on IgG versus IgE antibody-secreting cells in vitro. Journal of Immunological Methods, 2012, 375, 7-13.	1.4	8
46	A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children. PLoS ONE, 2011, 6, e22525.	2.5	70
47	Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D. PLoS ONE, 2011, 6, e18559.	2.5	41
48	Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Vaccine, 2010, 28, 6698-6703.	3.8	63
49	Safety and immunogenicity of GMZ2 — a MSP3–GLURP fusion protein malaria vaccine candidate. Vaccine, 2009, 27, 6862-6868.	3.8	98
50	The lîºB Kinase Complex and NF-îºB Actas Master Regulators of Lipopolysaccharide-Induced Gene Expressionand Control Subordinate Activation of AP-1. Molecular and Cellular Biology, 2004, 24, 6488-6500.	2.3	152
51	Lymphotoxin and lipopolysaccharide induce NFâ€̂ºBâ€p52 generation by a coâ€translational mechanism. EMBO Reports, 2003, 4, 82-87.	4.5	118
52	Invasion of Human Epithelial Cells byPseudomonas aeruginosa Involves Src-Like Tyrosine Kinases p60Src and p59Fyn. Infection and Immunity, 2001, 69, 281-287.	2.2	83